Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Quantification of ErbB3 receptor density on human breast cancer cells, using a stable radio-labeled mutant of NRG1beta.

Biochemical and biophysical research communications - 9 Jan 2009

van der Woning Sebastian P, van Zoelen Everardus J J

Abstract excerpt

ErbB3 transactivation can make tumor cells resistance to ErbB1/ErbB2 targeting drugs. This urges for a reliable method to determine cell surface ErbB3 levels, but in our hands iodinated NRG1beta is unstable and tends to underestimate the number of ErbB3 receptors in a radio-receptor assay. Here we show by the use of a radio-labeled high affinity neuregulin mutant NRG/YYDLL that ErbB3 levels can be determined in a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Binding, Competitive
Share to Intercellular Signaling Peptides and Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Iodine Radioisotopes

Share to Isotope Labeling

Share to Neuregulin-1

Share to Radioligand Assay

Share to Receptor, ErbB-3

Share to Receptor, ErbB-4

Source

Identifiers

PMID: 19026613
DOI: 10.1016/j.bbrc.2008.11.034

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Quantification of ErbB3 receptor density on human breast cancer cells, using a stable radio-labeled mutant of NRG1beta.PMID 19026613Read ↗

Inter-conversion of neuregulin2 full and partial agonists for ErbB4.Semantic proximity Read ↗

erbB3 is an active tyrosine kinase capable of homo- and heterointeractions.Semantic proximity Read ↗

The immunoglobulin‐like domain of neuregulins potentiates ErbB3/HER3 activation and cellular proliferationSemantic proximity Read ↗

Vascular endothelial growth factor receptor-3 promotes breast cancer cell proliferation, motility and survival in vitro and tumor formation in vivoSemantic proximity Read ↗

Neuregulin 1 expression is a predictive biomarker for response to AV-203, an ERBB3 inhibitory antibody, in human tumor models.Semantic proximity Read ↗

Co‐expression of neuregulins 1, 2, 3 and 4 in human breast cancerSemantic proximity Read ↗

Fibroblast growth factor receptors (FGFRs) localize in different cellular compartments. A splice variant of FGFR-3 localizes to the nucleus.Semantic proximity Read ↗

c-erbB-3Semantic proximity Read ↗

c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer.Semantic proximity Read ↗

Approaches to Multireceptor Targeting: Hybrid Radioligands, Radioligand Cocktails, and Sequential Radioligand ApplicationsSemantic proximity Read ↗

Clinical significance of poor CD3 response in head and neck cancer.Semantic proximity Read ↗

c‐erbB‐3 protein expression in human breast cancer: comparison with other tumour variables and survivalSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.